PRECIGEN, INC. Restricted Cash and Cash Equivalents, Noncurrent
PRECIGEN, INC. (PGEN) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2025-03-19
- 2024-12-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2024-09-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2024-06-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2024-03-31: Restricted Cash and Cash Equivalents, Noncurrent $265.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-19 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 |
| 2024-03-31 | $265.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $270.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $259.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $406.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $406.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $399.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $366.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $390.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $414.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $423.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $432.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $443.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $438.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $458.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $437.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $419.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $410.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $418.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $407.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $424.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $419.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $427.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | $433.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $436.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $460.00K 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $447.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |